Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 1, 2007, Pages 25-35

  Sarma, Pakala K S ^a   Tandon, Ruchi ^a   Gupta, Praful ^a   Dastidar, Sunanda G ^a   Ray, Abhijit ^a   Das, Biswajit ^a   Cliffe, Ian A ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Dual inhibitor; IGF 1 receptor; Insulin receptor; Small molecule inhibitor

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; AEW 541; AG 538; AGL 2263; ALDEHYDE DERIVATIVE; AMIDE; BENZAZEPINE DERIVATIVE; BENZAZOCINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BMS 536924; BMS 554417; BMS 577098; BVT 51004; CARBOXYLIC ACID DERIVATIVE; DAU 21834; ERLOTINIB; GB 21; IMATINIB; MELPHALAN; NVP ADW 742; PODOPHYLLOTOXIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SOMATOMEDIN C RECEPTOR; TETRAHYDROISOQUINOLINE DERIVATIVE; TYRPHOSTIN AG 213; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NONHUMAN; PROTEIN DOMAIN; REVIEW; TUMOR CELL;

EID: 33846126268     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.1.25     Document Type: Review

References (42)

1. HUBBARD SR: Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J (1997) 16:5572-5581.
2. ULLRICH A, GRAY A, TAM AW et al.: Insulin-like growth factor 1 receptor primary structure: comparison with insulin receptor suggest structural determinants that define functional specificity. EMBO J. (1986) 5:2503-2512.
3. WERNER H, WOLOSCHAK M, STANNARD B et al.: The insulin-like growth factor-1 receptor: molecular biology, heterogeneity and regulation. In: Insulin-like Growth Factors. Molecular and Cellular Aspects. LeRoith D (Ed.). CRC Press. Boca Raton, Florida (1991) 17-47.
4. PERUZZI F, PRISCO M, DEWS M et al.: Multiple signaling pathways of the insuhn-like growth factor 1 receptor in protection from apoptosis. Mol. Cell Biol. (1999) 19:7203-7215.
5. 3-kinase pathway. Endocr. J. (2000) 47:739-751.
6. DAUGHADAY WH, ROTWIEN P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr. Rev. (1989) 10:68-91.
7. BASERGA R, PERUZZI F, REISS K. IGF-1 Receptor in cancer biology. Int. J. Cancer (2003) 107:873-877.
8. BASERGA R: The insulin-like growth factor 1 receptor: a key to tumor growth? Cancer Res. (1995) 55:249-252.
9. YU H, ROHAN T. Role of insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. (2000) 92: 1472-1489.
10. LEROITH D, BASERGA R, HELMAN L, ROBERTS CT Jr: Insulin-like growth factors and cancer. Annl. Int. Med (1995) 122:54-59.
11. ARTEAGA CL: Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Canc. Res. & Treatment (1992) 22:101-106.
12. SACHDEV D, LI SL, HARTELL JS et al.: A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Canc. Res. (2003) 63:627-635.
13. DUNN SE, EHRLICH M, SHARP NJ et al.: A dominant negative mutant of the insulin-like growth factor- 1 receptor inhibits the adhesion, invasion and metastasis of breast cancer. Canc. Res. (1998) 58:3353-3361.
14. CHERNICKY CL, YI L, TAN H et al.: Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential and prolongs survival in vivo. Canc. Gene Therapy (2000) 7:384-395.
15. COPPOLA D, FERBER M, MIURA C et al.: A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. Cell Biol. (1994) 14:4588-4595.
16. HURBIN A, DUBREZ L, COLL JL, FAVROT MC: Inhibition of apoptosis by amphiregulin via an insulin-like growth factor- 1 receptor-dependent pathway in non-small cell lung cancer cell lines. J. Biol Chem. (2002) 277:49127-49133.
17. KNOWLDEN JM, HUTCHESON IR, BARROW D et al.: Insulin-like growth factor-1 receptor signaling in tamoxefin resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology (2005) 146:4609-4618.
18. NAHTA R, YUAN LY, ZHANG B et al.: Insulin-like growth factor-1 receptor/ human epidermal growth factor receptor-2 heterodimerization contributes to trastuzmab, resistance of breast cancer cells. Cancer Res. (2005) 65:11118-11128.
19. HOFMANN F, GARCIA-ECHEVERRIA C: Blocking insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov. Today (2005) 10:1041-1047.
20. BRODT P, SAMANI A, NAVAB R. Inhibition of the type I insulin-like growth factor receptor expression and signaling. novel strategies for antimetastatic therapy. Biochem. Pharmacol. (2000) 60:1101-1107.
21. GARCIA-ECHEVERRIA C: Medicinal chemistry approaches to target the kinase activity of IGF- 1R. IDrugs (2006) 9(6):415-419.
22. WEINER LM, BORGHAEI H: Targeted therapies in solid tumors: monoclonal antibodies and small molecules. Hum. Antibodies (2006) 15:103-111.
23. 42nd American society of clinical oncology annual meeting, Georgia world congress center, Atlanta Georgia. 2-6 June (2006).
24. ZHANG H, YEE D: The therapeutic potential of agents targeting the type-1 insulin-like growth factor receptor. Expert Opin. Invest. Drugs (2004) 13:1569-1577.
25. 2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood (2006) 107:669-678.
26. HOPFNER M, HUETHER A, SUTTER AP et al.: Blockade of IGF-1 receptor kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem. Pharmacol. (2006) 71:1435-1448.
27. PARANG K, SUN G: Design strategy for protein kinase inhibitors. Curr. Opin. Drug Discov. Dev. (2004) 7:617-629.
28. FISCHER PM: The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem. (2004) 11:1563-1583.
29. WITTMAN M, CARBONI J, ATTAR R et al.: Discovery of a 1H-Benzoimidazole-2-ol-1H-Pyrridine-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vitro anti tumor activity. J. Med. Chem. (2005) 48:5639-5643.
30. KISELYOV A, BALAKIN KV, TKACHENKO SE, SAVCHUK NP: Recent progress in the development of non-ATP competitive small-molecule inhibitors of protein kinases. Mini Rev. Med, Chem. (2006) 6:109-120
31. BELL IM, STIRDIVAHT SM, AHERN J et al.: Biochemical and structural characterization of a novel class of inhibitors of the type I insulin-like growth factor and insulin receptor kinases. Biochemistry (2005) 44:9430-9440.
32. EVARELLO P, VILLA M: Cyclin-dependent kinase inhibitors: a survey of the recent patent literature. Expert Opin. Ther. patents (2005) 15:675-703.
33. 96th annual meeting of the American association for cancer research, Anaheim California. 16-20 April (2005) 96.
34. WESTWELL AD: An inhibitor of insulin-like growth factor- 1 receptor kinase with in vivo anti tumor activity. Drug Discov. Today (2005) 10:1703-1704.
35. HALUSKA P, CARBONI J M, LOEGERING DA et al.: In vitro and in vivo anti-tumor effect of the dual insulin-like growth factor-1 insulin receptor inhibitor, BMS-554417. Cancer Res. (2006) 66:362-371.
36. SCAPIN G: Structural biology in drug design. Selective protein kinase, inhibitors. Drug Discov. Today (2002) 7:601-611.
37. KLEIN S, LEVITZIG A: Signal transduction therapy for cancer-whither now? Curr. Sig. Transd. Therapy (2006) 1:1-12.
38. BLUM G, GAZIT A, LEVITZKI A. Substrate competitive inhibitors of IG-1 receptor kinase. Biochemistry (2000) 39:15705-15712.
39. BLUM G, GAZIT A, LEVITZKI A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J. Biol. Chem. (2003) 278:40442-40454.
40. GIRNITA A, GIRNITA L, PRETE F etal.: Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. (2004) 64:236-242.
41. GABLE K L, MADDUK BA, PENARANDA C et al.: Diarylureas are small-molecule inhibitors of insulin-like growth factor 1 receptor signaling and breast cancer cell growth. Mol. Cancer Therapy (2006) 5:1079-1086.
42. TRAXLER P: Tyrosine kinases as targeted in cancer therapy - successes and failures. Expert Opin. Ther, Targets (2003) 7:215-234.